Tags

Type your tag names separated by a space and hit enter

Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
Antiviral Res. 2010 May; 86(2):180-7.AR

Abstract

Induction of mucosal immunity through oral immunization is an effective way to control influenza infection. In this study, baculovirus displaying influenza hemagglutinin was encapsulated within a reverse micelle structure of phosphatidylcholine and delivered into the gastrointestinal tract of mice to study its efficacy as an oral vaccine against cross-clade H5N1 infection. Mice vaccinated with encapsulated baculovirus displaying HA (En-BacHA) showed significantly enhanced HA specific serum IgG and mucosal IgA antibodies, and higher hemagglutination inhibition (HI) titers, when compared to its non-encapsulated form (BacHA). Estimation of serum neutralizing antibodies also indicated that En-BacHA formulation was able to induce strong cross-clade neutralization against heterologous H5N1 strains (clade 1.0, clade 2.1, clade 4.0 and clade 8.0). Further, mice vaccinated with En-BacHA alone were able to confer 100% protection against 5MLD50 of HPAI heterologous H5N1 strain (clade 1). Inclusion of recombinant cholera toxin B subunit as a mucosal adjuvant in the vaccine formulation did not show any significant effect in both systemic and mucosal immune responses. Oral delivery of encapsulated recombinant H5 HA expressed on baculovirus surface is an effective way to prime the immune system against H5N1 infection in mice and will have no biosafety concerns associated with their production or administration.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Prabakaran M
Animal Health Biotechnology, Temasek Life Sciences Laboratory, National University of Singapore, Singapore, Singapore.
Madhan S
No affiliation info available
Prabhu N
No affiliation info available
Geng GY
No affiliation info available
New R
No affiliation info available
Kwang J
No affiliation info available

MeSH

Adjuvants, ImmunologicAdministration, OralAnimalsAntibodies, NeutralizingAntibodies, ViralBaculoviridaeCholera ToxinCross ReactionsFemaleGenetic VectorsHemagglutination Inhibition TestsHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin AImmunoglobulin GInfluenza A Virus, H5N1 SubtypeInfluenza VaccinesMiceMice, Inbred BALB CMucous MembraneOrthomyxoviridae InfectionsSurvival Analysis

Pub Type(s)

Journal Article

Language

eng

PubMed ID

20153776

Citation

Prabakaran, Mookkan, et al. "Reverse Micelle-encapsulated Recombinant Baculovirus as an Oral Vaccine Against H5N1 Infection in Mice." Antiviral Research, vol. 86, no. 2, 2010, pp. 180-7.
Prabakaran M, Madhan S, Prabhu N, et al. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice. Antiviral Res. 2010;86(2):180-7.
Prabakaran, M., Madhan, S., Prabhu, N., Geng, G. Y., New, R., & Kwang, J. (2010). Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice. Antiviral Research, 86(2), 180-7. https://doi.org/10.1016/j.antiviral.2010.02.315
Prabakaran M, et al. Reverse Micelle-encapsulated Recombinant Baculovirus as an Oral Vaccine Against H5N1 Infection in Mice. Antiviral Res. 2010;86(2):180-7. PubMed PMID: 20153776.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice. AU - Prabakaran,Mookkan, AU - Madhan,Selvaraj, AU - Prabhu,Nayana, AU - Geng,Grace Yuhong, AU - New,Roger, AU - Kwang,Jimmy, Y1 - 2010/02/12/ PY - 2009/11/30/received PY - 2010/01/12/revised PY - 2010/02/08/accepted PY - 2010/2/16/entrez PY - 2010/2/16/pubmed PY - 2010/6/22/medline SP - 180 EP - 7 JF - Antiviral research JO - Antiviral Res VL - 86 IS - 2 N2 - Induction of mucosal immunity through oral immunization is an effective way to control influenza infection. In this study, baculovirus displaying influenza hemagglutinin was encapsulated within a reverse micelle structure of phosphatidylcholine and delivered into the gastrointestinal tract of mice to study its efficacy as an oral vaccine against cross-clade H5N1 infection. Mice vaccinated with encapsulated baculovirus displaying HA (En-BacHA) showed significantly enhanced HA specific serum IgG and mucosal IgA antibodies, and higher hemagglutination inhibition (HI) titers, when compared to its non-encapsulated form (BacHA). Estimation of serum neutralizing antibodies also indicated that En-BacHA formulation was able to induce strong cross-clade neutralization against heterologous H5N1 strains (clade 1.0, clade 2.1, clade 4.0 and clade 8.0). Further, mice vaccinated with En-BacHA alone were able to confer 100% protection against 5MLD50 of HPAI heterologous H5N1 strain (clade 1). Inclusion of recombinant cholera toxin B subunit as a mucosal adjuvant in the vaccine formulation did not show any significant effect in both systemic and mucosal immune responses. Oral delivery of encapsulated recombinant H5 HA expressed on baculovirus surface is an effective way to prime the immune system against H5N1 infection in mice and will have no biosafety concerns associated with their production or administration. SN - 1872-9096 UR - https://www.unboundmedicine.com/medline/citation/20153776/Reverse_micelle_encapsulated_recombinant_baculovirus_as_an_oral_vaccine_against_H5N1_infection_in_mice_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0166-3542(10)00344-X DB - PRIME DP - Unbound Medicine ER -